What's happened
A Nature Medicine trial finds that adding the monoclonal antibody apitegromab to tirzepatide for weight loss preserves lean mass and strength, with all participants losing similar total weight but those on apitegromab retaining more muscle. Researchers urge larger studies while doctors stress ongoing activity and nutrition to maintain muscle.
What's behind the headline?
Key takeaways
- A 24‑week trial with 102 overweight/obese individuals shows similar total weight loss between groups, but higher lean-mass retention with apitegromab.
- The finding could reduce muscle loss associated with GLP-1 therapies, potentially preserving strength and function.
- Limitations include a small sample and short duration; broader safety and efficacy data are needed.
Implications
- If validated, the approach could become a targeted option for patients prioritizing muscle preservation during weight loss.
- Healthcare providers may need to balance efficacy with cost, accessibility, and the therapy’s safety profile.
How we got here
GLP-1 drugs like tirzepatide (Mounjaro/Zepbound) drive weight loss but commonly reduce lean body mass. A Nature Medicine study tests apitegromab, a myostatin inhibitor, to see if it preserves lean mass during weight loss.
Our analysis
The study is published in Nature Medicine; coauthor quotes highlight muscle preservation, with commentary from obesity and cardiometabolic experts on the need for larger trials. - Seeley et al., Nature Medicine (2026).
Go deeper
- Could this combo become standard for patients on GLP-1 therapies?
- What are the safety considerations for long-term use of apitegromab?
More on these topics
-
Nature Medicine - Peer-reviewed journal
Nature Medicine is a monthly peer-reviewed medical journal publishing research articles, reviews, news and commentaries in the biomedical area, including both basic research and early-phase clinical research covering all aspects of medicine.